Evaluation of a New Catheter Coating Process for Urinary Catheters Used for Intermittent Catheterization.

Evaluation of a New Catheter Coating Process for Urinary Catheters Used for Intermittent Catheterization - A Prospective, Blinded, Randomized, Cross-over, Multicenter Study

This is a prospective, double-blinded, randomized, multi-centre, cross-over study. All subjects will use both the study device (test catheter) and the comparator (control catheter) for one week each.

Study Overview

• Status: Completed
• Conditions: Intermittent Urethral Catheterization
• Intervention / Treatment: Device: Treatment Period One; Device: Treatment Period Two

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Sweden
  • Borås, Sweden, 503 32
    • Urologcentrum Borås
  • Gothenburg, Sweden, 405 45
    • Urologkliniken vid Carlanderska AB
  • Halmstad, Sweden, 302 46
    • Specialistmottagningen i Urologi, Halmstad
  • Karlstad, Sweden, 651 85
    • Urologmottagningen, Centralsjukhuset Karlstad
  • Stockholm, Sweden, 117 94
    • GHP Urologcentrum Stockholm
  • Torsby, Sweden, 685 34
    • Uroterapimottagningen, Sjukhuset Torsby
  • Uppsala, Sweden, 751 85
    • Urologmottagningen, Akademiska sjukhuset
  • Örebro, Sweden, 701 85
    • Urologiska kliniken, Urologmottagningen Universitetssjukhuset Örebro

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Provision of informed consent.
• Males, aged 18 years and over.
• Maintained urethra sensibility as judged by the subject. (Can you feel the catheter during catheterization? Yes.).
• Practice CIC at least 2 times daily.
• Using catheters in the size CH 12 or CH 14, Nelaton tip, and able to use catheter length of 40 cm.
• Experienced users of CIC defined as a minimum of three months on therapy.
• Adults able to read, write and understand information given to them regarding the study.

Exclusion Criteria:

• Ongoing, symptomatic UTI at enrolment as judged by investigator. The definition of UTI, is a positive urine culture of ≥103 CFU/ml of ≥1 bacterial species and presence of symptoms or signs compatible with UTI with no other identified source of infection.
• Known urethral stricture which, in the opinion of the investigator, could influence the subject's evaluation of the catheters.
• Involvement in the planning and conduct of the study (applies to both WHC staff and staff at the study site).
• Previous enrolment or randomisation of treatment in the present study.
• Simultaneous participation in another clinical study that may impact the primary endpoint.
• Severe non-compliance to protocol as judged by the investigator

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment Period One; LoFric, hydrophilic urinary catheter for single use. The study device is based on commercially available hydrophilic urinary catheters for intermittent catheterization, but with a different coating process than the comparator. Treatment Period One will last 1 week.	Device: Treatment Period One; LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
Active Comparator: Treatment Period Two; CE-marked LoFric®, hydrophilic urinary catheter for single use. The comparator product is today commercially available and produced by WHC. Treatment Period Two will last 1 week.	Device: Treatment Period Two; CE-marked LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tolerability of practicing CIC by using two urinary catheters produced with different coating processes measuring change over time by means of subjective assessment scales	The primary objective of this study is to compare the subjects' tolerability of practising CIC by using two urinary catheters produced with different coating processes by means of subjective assessment scales.	2 weeks in total. 1 week Treatment Period One/1 week Treatment Period Two

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tolerability with regards to perceived pain, when using two different urinary catheters; test vs control catheter.	AE/SAE/ADE/SADE reporting/PRO variables. Assessed in patient questionnaire for each subject. A 5 graded scale will be used to determine the perception and the severity of each variable. The difference between the treatments will be calculated for each subject.	2 weeks in total. 1 week Treatment Period One/1 week Treatment Period Two. Safety variables spontaneously reported during whole study period
Tolerability with regards to presence of bleeding, when using two different urinary catheters; test vs control catheter	AE/SAE/ADE/SADE reporting /PRO variables. Assessed in patient questionnaire for each subject. A 5 graded scale will be used to determine the perception and the severity of each variable. The difference between the treatments will be calculated for each subject.	2 weeks in total. 1 week Treatment Period One/1 week Treatment Period Two. Safety variables spontaneously reported during whole study period
Tolerability with regards to perceived "other discomfort", when using two different urinary catheters; test vs. control catheter	PRO variables. Frequency of "other discomfort" (yes/ no) will be assessed in patient questionnaire. The frequency of "other discomfort" will be compared between the treatments. "Other discomfort" will be further specified using 5 graded scale (as for the other variables on the 5 graded scale the difference between the treatments will be calculated for each subject).	2 weeks in total. 1 week Treatment Period One/1 week Treatment Period Two. Safety variables spontaneously reported during whole study period
Perception of the catheter's slipperiness, smoothness, flexibility, usability, and resistance, when practicing intermittent self-catheterization with urinary catheters; test vs. control catheter	PRO variables. Assessed in patient questionnaire for each subject. A 5 graded scale will be used to determine the perception and the severity of each variable. The difference between the treatments will be calculated for each subject.	2 weeks in total. 1 week Treatment Period One/1 week Treatment Period Two. Safety variables spontaneously reported during whole study period
To evaluate subject satisfaction with catheter; test vs. control catheter.	PRO variables. Assessed in patient questionnaire for each subject. A 5 graded scale will be used to determine the satisfaction. The difference between the treatments will be calculated for each subject.	2 weeks in total. 1 week Treatment Period One/1 week Treatment Period Two. Safety variables spontaneously reported during whole study period
Total number of DD/AE/SAE/ADE/SADE/ USADE.	Total number of DD/AE/SAE/ADE/SADE/ USADE observed by the study personnel or spontaneously reported from subject will be calculated. The frequency of DD/AE/SAE/ADE/SADE/ USADE will be calculated for each treatment group.	2 weeks in total.

Collaborators and Investigators

• Sponsor: Dentsply International
• Collaborators: Wellspect HealthCare

Study record dates

Study Major Dates

• Study Start (Actual): August 29, 2018
• Primary Completion (Actual): November 19, 2018
• Study Completion (Actual): November 19, 2018

Study Registration Dates

• First Submitted: September 17, 2018
• First Submitted That Met QC Criteria: September 24, 2018
• First Posted (Actual): September 26, 2018

Study Record Updates

• Last Update Posted (Actual): December 5, 2018
• Last Update Submitted That Met QC Criteria: December 4, 2018
• Last Verified: December 1, 2018

More Information

Terms related to this study

• Other Study ID Numbers: LOF-0034

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No